Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies

As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zumla, Alimuddin, Wang, Fu-Sheng, Ippolito, Giuseppe, Petrosillo, Nicola, Agrati, Chiara, Azhar, Esam I., Chang, Chao, El-Kafrawy, Sherif A., Osman, Mohamed, Zitvogel, Laurence, Galle, Peter R., Locatelli, Franco, Gorman, Ellen, Cordon-Cardo, Carlos, O’Kane, Cecilia, McAuley, Danny, Maeurer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231497/
https://www.ncbi.nlm.nih.gov/pubmed/32425638
http://dx.doi.org/10.1016/j.ijid.2020.05.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231497/
https://www.ncbi.nlm.nih.gov/pubmed/32425638
http://dx.doi.org/10.1016/j.ijid.2020.05.040

Ejemplares similares